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“What is your research about?” they ask me.
“Alzheimer’s disease” I respond.
“Ah great! We will definitely need you in a couple of years!” they 
say in a tone mingling excitement and fear for the future.
Valorization9
This is one of the most common reactions I receive once I try to explain what I do 
for a living to my relatives. 
My relatives: middle-aged common people with mostly office jobs receiving 
input of a wide gamut of diseases that might affect them in the coming years, 
and amidst them Alzheimer’s disease, the seemingly most terrifying one. These 
people put their hope in individuals like me in order to treat a disease that could 
gradually erase their lifetime memories and their timeline thus far.
Me: a researcher on my 4th year of working experience attempting to gain a 
little more insight in the widely undiscovered world of epigenetics and complex 
diseases through a computer screen and huge datasets or animal experiments. 
The aforementioned reaction does not put me at ease, as I am aware that should 
any of them develop Alzheimer’s disease in the next decades, there may be 
nothing we can do; the time bomb has most likely been set to go off already and 
although help is on the way, it may be too late for them. 
Currently, on average, for every day of an Alzheimer’s disease researcher’s 
life, 16,437 people are being diagnosed with the disease, which translates 
in a devastating sum of 6 million new cases annually, worldwide, adding an 
immense burden on families, caregivers and financial costs for society [1]. 
Should Alzheimer’s disease get eradicated, annual savings from payments for 
all American dementia patients could pay off the Greek government debt [2]. 
Similarly, burdensome is the scourge of mental illnesses with almost 40% of the 
developed countries population being diagnosed with a mental disorder, which 
corresponds to approximately 164.8 million people affected [3]. The need for a 
therapy is imperative. Nevertheless, this intense global scientific scouting around 
for treatment strategies has not reported back that many encouraging results. 
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While it is a fact that the lack of effective therapeutics is mainly due to the overly 
complicated nature of such disorders, one could also claim that the majority of 
research lines are restricted to pathological observations made decades ago and 
researchers seem rather skeptical to leap towards more innovative hypotheses. 
Scientists supported that their arsenal was lying within the genetic code, and 
expected that upon decoding the whole human genome in 2003, answers 
concerning causality and aetiopathogenesis would emerge. However, they soon 
realized that complex disorders, such as Alzheimer’s disease, schizophrenia, 
bipolar disorder, are not of genetic origin only, but to a big extend depend on 
the impact of the environment, which plays an important role in their onset and 
progression. From then on, the field of epigenetics burgeoned and, thus, empirical 
basis was set for the speculative nature of the implication and mechanisms of 
epigenetic modification on disease pathogenesis. Therefore one might wonder: 
“could it be that for the last 4 decades the scientific world has been fighting the 
wrong adversaries?”.
The work presented in this dissertation attempts to respond to this question 
by examining “unusual suspects” among players of disease pathology and 
pathogenesis. These “unusual suspects” are not only restricted to epigenetic 
mechanisms, but also extend to brain structures with previously underrecognized 
roles in disease pathogenesis and pathology. Most possibly this book will not 
have a directly observable impact on society or economy, but it is highly relevant 
for the academic enterprise. The majority of the chapters represent an exploratory 
body of work applied on human tissue specimens that could serve as pillars and 
thus maneuver future studies towards novel directions. 
To this end, the research presented in CHAPTER 3 is an interrogation of specific 
epigenetic modifications associated with Alzheimer’s disease. The impact of 
this work on the scientific world lies in two levels. Firstly, being among the first 
of its kind to simultaneously examine three cytosine states, it does indicate that 
methylation and hydroxymethylation marks highly differ even in the same genetic 
locus and thus advocates that previously reported studies on methylation which 
looked into the combined signal of methylation and hydroxymethylation should 
be reviewed with caution. Secondly, in retrospect, one could claim that the 
conception of this study is highly relevant for society due to the novel view in a 
different brain structure. In contrast to the majority of the hippocampus/memory 
deficits-targeted research lines, the hypothesis driving this project is tailored to 
the most incipient preclinical disease manifestations that a patient experiences, 
and therefore considers the understudied brainstem structures [4]. While such 
study requires replication in order to highlight the validity of the outcomes, it might 
nominate novel targets, relevant to earlier stages of the disease, that can be used 
for diagnostic or treatment alternatives in future studies. 
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Similarly, the work presented in CHAPTER 5 is an effort to define epigenetic 
signatures associated with mental disorders, namely schizophrenia and bipolar 
disorder. The novelty of this study lays in the interrogation of epigenetic marks in 
the understudied cerebellum. And indeed its impact is rather big as, regardless 
the small sample size of the cohort, the most differentially methylated regions were 
replicated in an independent cohort. Further mechanistic approaches are required 
in order to functionally characterize the meaning of this epigenetic signature at 
a systems level as well as cross-regionally in the brain with the ultimate goal of 
using the identified markers as preventive or diagnostic tools. 
In the interim, the stature of epigenome-wide studies like the ones presented 
in CHAPTER 3 and 5 is the broadening of knowledge until a more holistic 
understanding of the pathological underpinnings of these diseases is reached. 
Novel approaches covering previously underrecognized brain areas while 
employing internationally used methodologies, namely the Illumina arrays, add 
one more brick to this global effort to comprehend the width and depth of the 
biological mechanisms making an individual susceptible to Alzheimer’s disease, 
schizophrenia or bipolar disease.  
The project presented in CHAPTER 4 does not solely focus on brain material, 
but on blood as well, which makes it more clinically relevant as well as more 
possible to have a societal impact. The blood is an easy accessible platform 
to study epigenetic changes throughout the lifespan and thus attempt to model 
epigenetic marker fluctuations during the onset and progression of a disease. 
Furthermore, blood markers could also be indicative of central events related with 
the outbreak of the pathology. To this end, changes in the i.e. methylation state 
of a genetic locus, or, to be more realistic, a combination of them, could indicate 
the conversion of a healthy person to an AD patient and therefore a simple blood 
test could serve as a diagnostic and/or prognostic tool. 
The scientific work concluding this dissertation in CHAPTER 6 tackles the main 
clinical symptom of Alzheimer’s disease, memory loss, with the assistance of 
animal models. Excitingly, the administered compound that targets the BDNF/
TrkB signaling system, managed to restore the memory impairment in a transgenic 
mouse model of Alzheimer’s disease. However, what is the impact of this outcome? 
Perusing the literature, every week, another article gets published suggesting to 
have cured Alzheimer’s disease in animal models. Still, regardless this tremendous 
‘success’ rate, no effective, disease-eradicating treatment has been introduced 
to the market yet [5]. Under no circumstances should the importance of animal 
models be undermined, as they are the impetus of fundamental research, but yet 
again, the current animal models fail to portray the disease in an accurate and 
global manner, crashing the hopes for the successful translation to the human 
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situation.  At this point I would like to clarify  that intervention studies like this one 
cannot provide a shortcut to the cure. However, the significance of this research 
line lies in the fact that modulation of a fundamental signaling pathway seems 
to have beneficial effects in memory performance and therefore adds one more 
piece to the puzzle of the pathophysiology of Alzheimer’s disease. 
So upon reflection of the impact my work will have in various levels, I stay 
puzzled. The environmental stimuli that could influence the vulnerability of our 
genome increase per decade, with the ever-changing pace of life. Worldwide, 
people of similar disciplines make a change for the humankind by finding cures 
for the most common disorders. The lifespan thus is extended; but is the quality of 
the 30-40 prolonged years optimal? What society demands from scientists is a 
solution for all these three disorders, in the form of cure or prevention, as soon as 
possible. Eventually, holistic knowledge of epigenetics will offer novel alternatives 
to therapeutic approaches and/or fast and accurate diagnosis close enough to 
the onset of each disease. Hopefully by that time, personalized medicine will 
have progressed to the point that e.g. targeted epigenetic engineering will allow 
for an intervention that could cure the disease. Will this dissertation yield any 
therapeutic candidates? Wishfully yes. Of course it will not happen from one day 
to the next. Fundamental research is vital to set the pillars for applied research and 
to inspire researchers, generate novel ideas that eventually will lead to scientific 
breakthroughs. And for now, the fact that my research offers another stepping-
stone towards better understanding of the complex nature of the disorders makes 
all the efforts worthwhile.
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